REGENXBIO (RGNX) Stock Price, News & Analysis

Company Overview

REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses its proprietary NAV AAV Gene Delivery Platform to design adeno-associated virus (AAV) vectors intended to deliver therapeutic genes to targeted cells and tissues.

REGENXBIO’s pipeline has included investigational therapies for rare and genetic disorders, including Duchenne muscular dystrophy, Hunter syndrome, severe mucopolysaccharidosis type I, and homozygous familial hypercholesterolemia. Its programs are designed to address diseases affecting areas such as muscle, the central nervous system, and the liver. The company also licenses its NAV technology and collaborates with pharmaceutical companies, including Novartis, whose Zolgensma gene therapy was developed using a REGENXBIO-licensed AAV vector.

Founded in 2009 and headquartered in Rockville, Maryland, REGENXBIO conducts research and clinical development activities aimed at serving patients in the United States and international markets. The company’s leadership has included Kenneth T. Mills as president and chief executive officer, while its programs have advanced through internal development and strategic partnerships.

Key Stats

• Today's Range: $8.49 to $8.73
• 50-Day Range: $8.06 to $15.65
• 52-Week Range: $5.45 to $16.19
• Volume: 847,472 shs
• Average Volume: 1.28 million shs
• Market Capitalization: $573.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.27
• Consensus Rating: Moderate Buy

REGENXBIO Stock Analysis - MarketRank™

REGENXBIO scored higher than 76% of companies evaluated by MarketBeat, and ranked 175th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

REGENXBIO has a consensus price target of $23.27, representing about 167.8% upside from its current price of $8.69.

Amount of Analyst Coverage

REGENXBIO has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for REGENXBIO are expected to grow in the coming year, from ($3.91) to ($3.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of REGENXBIO is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of REGENXBIO is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

REGENXBIO has a P/B Ratio of 4.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.24% of the float of REGENXBIO has been sold short.

Short Interest Ratio / Days to Cover

REGENXBIO has a short interest ratio ("days to cover") of 4.87.

Change versus previous month

Short interest in REGENXBIO has recently decreased by 8.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

REGENXBIO does not currently pay a dividend.

Dividend Growth

REGENXBIO does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.14

News Sentiment

REGENXBIO has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for REGENXBIO this week, compared to 7 articles on an average week.

Search Interest

Only 2 people have searched for RGNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $718,232.00 in company stock.

Percentage Held by Insiders

14.22% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/14/2026
• 2026 Global Healthcare Conference: 9/15/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/16/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGNX
• CIK: 1590877
• Web: www.regenxbio.com
• Phone: (240) 552-8181
• Fax: N/A
• Employees: 371
• Year Founded: 2009

Price Target and Rating

• Average Price Target for REGENXBIO: $23.27
• High Price Target: $50.00
• Low Price Target: $12.00
• Potential Upside/Downside: +167.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.62
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$193.88 million
• Net Margins: -112.58%
• Pretax Margin: -112.58%
• Return on Equity: -220.07%
• Return on Assets: -46.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.86
• Quick Ratio: 2.86

Sales & Book Value

• Annual Sales: $170.44 million
• Price / Sales: 3.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.03 per share
• Price / Book: 4.28

Miscellaneous

• Outstanding Shares: 66,010,000
• Free Float: 56,626,000
• Market Cap: $573.63 million
• Optionable: Optionable
• Beta: 0.94